In the treatment of SCLC, combining PD-L1 mAb atezolizumab/durvalumab with etoposide plus platinum (EP) chemotherapy has become the standard treatment for extensive-stage SCLC, prolonging OS by 2–3 months.110. The gene discussed is CD274; the disease is small cell lung carcinoma.